MARKET WIREReuters • 2h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why FENC Stock advanced +0.74% Today — RQD Quant Desk Flash
$10.95 +0.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $10.94
Fennec Pharmaceuticals Inc. (FENC) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $383.6M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $10.94 (-0.06%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-9.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FENC)Realized 20D OHLCV Swing Band: ±11.1%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY FENC SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+10/20 pts (28% of score)
FRED Regime × Technicals: 70% of 52W Range • RSI-14 at 45.5 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (25% of score)
20D Institutional Volume Accumulation (±11.1% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$10.71-6.8% Next Q
28
Q2 (-2Q)Grade E$9.98+1% Next Q
31
Q3 (-1Q)Grade E$10.08+8.6% Next Q
33
CurrentGrade D-$10.95-8.3% Hist 90D α
36
Trajectory: E (28) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a FENC Turnaround Squeeze
While FENC currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.93) and Max Pain ($11.50) forces dealer call-delta covering toward $13.91.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $FENC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “FENC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why FENC Stock advanced +0.74% Today — RQD Quant Desk Flash
Fennec Pharmaceuticals Inc. (FENC) advanced +0.74% to $10.95, trading at 70% of its 52-week range ($5.65 – $13.25). Stretched risk/reward at current multiples (-26% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 70% of its 52-week range ($5.65 – $13.25) with RSI-14 at 45.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.1% around $10.95 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live FENC Headlines & Catalysts
MARKET WIRECNBC • 4h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 4h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 6h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 7h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 8h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 8h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 9h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FENC)
- ✓Walkthrough of FENC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
FENC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +68.72%▲ ASCENDING CHANNEL
2026-10-30O $10.89H $11.05L $10.14C $10.95VOL 195.7K
RES: $16.10SUP: $9.95SMA50: $10.93SMA200: $9.21
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
FENC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -6.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on FENC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for FENC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FENC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FENC)
Health Care Rank #782 of 1016
⚔️ AGMB vs FENC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (FENC vs. AGMB, TRXB, ZURA, TECX)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Fennec Pharmaceuticals Inc. (FENC) ranks #782 by composite RQD confidence (36/100, grade D-) and #486 by equity capitalization ($383.6M). Within this direct 5-issuer industry benchmark cohort, FENC leads on earnings valuation at N/A trailing P/E, while FENC leads on capital efficiency and profitability with -25.9% ROIC and — gross margin. AGMB currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with FENC at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| FENC
ACTIVE
Fennec Pharmaceuticals Inc. | D- | 36/100 | — | — | -25.9% | +0.74% | $383.6M | Benchmark Subject |
| AGMB AgomAb Therapeutics NV | D | 51/100 | — | — | — | -0.13% | $391.5M | /agmb-vs-fenc → |
| TRXB TRex Bio Inc. | D | 49/100 | — | — | — | -6.31% | $371.1M | /trxb-vs-fenc → |
| ZURA Zura Bio Limited (Class A) | E | 29/100 | — | — | -35.0% | -11.49% | $370.9M | /zura-vs-fenc → |
| TECX Tectonic Therapeutic Inc. | D- | 37/100 | — | — | -35.0% | -0.29% | $400.8M | /tecx-vs-fenc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001211583In its most recent audited fiscal period (FY2025, filed 2025-12-31), Fennec Pharmaceuticals Inc. (FENC) reported GAAP revenue of $44.6M (-6.1% vs. FY2024 revenue of $47.5M , and +110.1% cumulative change since FY2023) , GAAP net income of -$9.74B, operating cash flow of -$12.5M, and free cash flow of -$12.5M (-146.2% YoY). On the balance sheet, FENC closed FY2025 with $70.6M in total assets against $0 in total debt (Altman Z-Score: 3.31, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $44.6M | -$9.74B | -$12.5M | -$12.5M | $70.6M | — |
| FY2024 (FY) | 2024-12-31 | $47.5M | -$436.0M | $27.0M | $27.0M | $44.9M | — |
| FY2023 (FY) | 2023-12-31 | $21.3M | -$16.05B | -$17.1M | -$17.1M | — | — |
3. FENC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs FENC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Fennec Pharmaceuticals Inc. (NASDAQ: FENC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $10.95 (+0.74% 1D, market cap $383.6M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FENC ranks #782 in composite RQD confidence.
How does FENC compare to AGMB and TRXB in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), FENC carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -25.9%. By comparison, AGMB (AgomAb Therapeutics NV) holds a D grade (51/100 RQD, P/E N/A, ROIC —, cap $391.5M) and TRXB (TRex Bio Inc.) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $371.1M). Among the 5-stock peer group, FENC leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for FENC?
Per FENC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001211583), Fennec Pharmaceuticals Inc. generated $44.6M in revenue (-6.1% YoY), -$9.74B in net income, and -$12.5M in free cash flow against $70.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is FENC trading relative to its 50-day, 200-day, and 52-week technical levels?
FENC last traded at $10.95 (+0.74% on volume of 180,573 shares), positioning the stock +0.18% above its 50-day simple moving average ($10.93) and +18.89% above its 200-day simple moving average ($9.21). Across its 52-week range of $5.65 to $13.25, FENC sits at the 69.7% percentile with a 14-day RSI of 45.5 (NEUTRAL RANGE) and an implied next-earnings move of ±11.1% ($9.73 to $12.17).
FENC Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is FENC stock moving today?
Why FENC Stock advanced +0.74% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-26% return on capital) under elevated 10-year interest-rate pressure.